Literature DB >> 2917586

Urinary excretion of 6 beta-hydroxycortisol and the time course measurement of enzyme induction in man.

E E Ohnhaus1, A M Breckenridge, B K Park.   

Abstract

The effect of enzyme induction by antipyrine, phenobarbitone and rifampicin on the time-course of urinary 6 beta-hydroxycortisol (6 beta-OHC) excretion was investigated in healthy volunteers. The drugs were given chronically for either seven or 14 days. Significant increases in 6 beta-OHC excretion were observed after 4 days administration of antipyrine (1.2 g), 13 days administration of phenobarbitone (100 mg), and only 2 days administration of rifampicin (0.6 or 1.2 g). During 14 days rifampicin administration (1.2 g) 6 beta-OHC excretion, for individual subjects, reached a maximum on Days 11-14 when excretion was significantly greater than on day 7. On stopping rifampicin, in a 7-day study, excretion decreased over the next six days, but still remained significantly elevated compared to the original control values. These studies show that measurement of urinary 6 beta-hydroxycortisol provides a simple non-invasive method with which to monitor the time-course of enzyme induction by drugs in man. However, the method cannot be used to predict clinically important drug interactions until the cytochrome P-450 enzyme responsible for cortisol 6 beta-hydroxylation has been fully characterized.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2917586     DOI: 10.1007/BF00561021

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

1.  [The acceleration of evipan oxidation and the demethylation of methylaminopyrine by barbiturates].

Authors:  H REMMER
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1959

Review 2.  6-Hydroxylation of cortisol and urinary 6beta-hydroxycortisol.

Authors:  S B Pal
Journal:  Metabolism       Date:  1978-08       Impact factor: 8.694

3.  Influence of turnover rates on the responses of enzymes to cortisone.

Authors:  C M Berlin; R T Schimke
Journal:  Mol Pharmacol       Date:  1965-09       Impact factor: 4.436

4.  Interindividual variations in drug disposition. Clinical implications and methods of investigation.

Authors:  D D Breimer
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

5.  Selection of subjects for investigation of host factors affecting drug response: a method to identify new pharmacogenetic conditions.

Authors:  E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1984-01       Impact factor: 6.875

6.  HPLC determination of antipyrine metabolites.

Authors:  M Eichelbaum; B Sonntag; H J Dengler
Journal:  Pharmacology       Date:  1981       Impact factor: 2.547

7.  A direct radioimmunoassay for 6 beta-hydroxycortisol in human urine.

Authors:  B K Park
Journal:  J Steroid Biochem       Date:  1978-10       Impact factor: 4.292

8.  Quantitative determination by HPLC of urinary 6beta-hydroxycortisol, an indicator of enzyme induction by rifampicin and antiepileptic drugs.

Authors:  I Roots; R Holbe; W Hövermann; S Nigam; G Heinemeyer; A G Hildebrandt
Journal:  Eur J Clin Pharmacol       Date:  1979-08       Impact factor: 2.953

9.  Effects of cimetidine on carbamazepine auto- and hetero-induction in man.

Authors:  G J Macphee; G G Thompson; G Scobie; E Agnew; B K Park; T Murray; K E McColl; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

10.  Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique.

Authors:  L Bertilsson; B Höjer; G Tybring; J Osterloh; A Rane
Journal:  Clin Pharmacol Ther       Date:  1980-01       Impact factor: 6.875

View more
  23 in total

Review 1.  Drug trials in children: problems and the way forward.

Authors:  S Conroy; J McIntyre; I Choonara; T Stephenson
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

2.  Pharmacokinetics of ruboxistaurin are significantly altered by rifampicin-mediated CYP3A4 induction.

Authors:  Kwee Poo Yeo; Stephen L Lowe; Ming Tung Lim; James R Voelker; Jennifer L Burkey; Stephen D Wise
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

Review 3.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

4.  Concurrent assessment of hepatic and intestinal cytochrome P450 3A activities using deuterated alfentanil.

Authors:  E D Kharasch; S Vangveravong; N Buck; A London; T Kim; J Blood; R H Mach
Journal:  Clin Pharmacol Ther       Date:  2011-02-23       Impact factor: 6.875

5.  Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.

Authors:  Helen C Swaisland; Malcolm Ranson; Robert P Smith; Joanna Leadbetter; Alison Laight; David McKillop; Martin J Wild
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

6.  Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects.

Authors:  A Hsu; G R Granneman; G Witt; C Locke; J Denissen; A Molla; J Valdes; J Smith; K Erdman; N Lyons; P Niu; J P Decourt; J B Fourtillan; J Girault; J M Leonard
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

7.  Factors Contributing to Fentanyl Pharmacokinetic Variability Among Diagnostically Diverse Critically Ill Children.

Authors:  Fanuel T Hagos; Christopher M Horvat; Alicia K Au; Yvette P Conley; Lingjue Li; Samuel M Poloyac; Patrick M Kochanek; Robert S B Clark; Philip E Empey
Journal:  Clin Pharmacokinet       Date:  2019-12       Impact factor: 6.447

8.  CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients.

Authors:  E A Sotaniemi; A Rautio; M Bäckstrom; P Arvela; O Pelkonen
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

9.  Two- and four-day rifampin chemoprophylaxis regimens induce oxidative metabolism.

Authors:  S M Borcherding; T L Bastian; T H Self; N Abou-Shala; B W LeDuc; R L Lalonde
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

10.  Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers.

Authors:  Y K Pithavala; M Tortorici; M Toh; M Garrett; B Hee; U Kuruganti; G Ni; K J Klamerus
Journal:  Cancer Chemother Pharmacol       Date:  2009-07-15       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.